Where does DeuteRx, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), DeuteRx, LLC ranks #15,954 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does DeuteRx, LLC hold?

DeuteRx, LLC holds 18 US utility patents granted between 2015 and 2024, spanning 6 technology areas.

What is DeuteRx, LLC's Innovation Score?

DeuteRx, LLC has an Innovation Score of 35.1 out of 100 (top 50% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does DeuteRx, LLC focus on?

DeuteRx, LLC's top technology area is C07D (Heterocyclic Compounds) with 16 patents, ranking #537 of 3,165 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is DeuteRx, LLC's patent grant rate increasing or decreasing?

DeuteRx, LLC's recent grant velocity is -62% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for DeuteRx, LLC's patents?

DeuteRx, LLC's patents average 20.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the DeuteRx, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

DeuteRx, LLC

USPTO PatentsView assignee record - 18 granted patents across 6 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Deuterx ranks #15,954 of 49,997 tracked US assignees by granted-patent volume, with 18 patents across 6 technology areas.

#15,954
of 49,997 US assignees by volume: Top 50%
by Innovation Score (35.1/100): 20.4
avg claims per patent: -62%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15954 · US Corporation #15,954 · 18 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 18 grants
MID-PACK #15,954/49,997
PHOTO-FINISH DeGen Medical
CPC-NARROW C07D · 6 areas
INNOV-THIN 35.1/100
CLAIMS-DENSE 20.4 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -62% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: DeGen Medical, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Deuterx’s 35.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.2 pts (29%) Velocity 4.0 pts (11%) Breadth 8.7 pts (25%) Claim depth 12.3 pts (35%)

Qualcomm Incorporated · highest

85
DeuteRx · this assignee

35
Envision Aesc… · near

35
GenMark Diagnostics · near

35
Optical Cable · near

35
W Morrison Consultin… · near

35
3D Lighting… · lowest

7

What this shows Deuterx's Innovation Score is 35.1/100 (top 50% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Deuterx?

Each dot is one of Deuterx’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Deuterx’s own 20.4 claims/patent is ABOVE the 15.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Deuterx vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Deuterx's grants concentrate

DeuteRx, LLC is a focused PatentsView assignee: 6 CPC subclasses with 88.9% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2017 (4 grants) versus a trough of 1 in 2020. By volume, Deuterx sits between DeGen Medical, Inc. and Dixie Consumer Products LLC.

Deuterx's three-year grant acceleration

DeuteRx, LLC shows 3 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Degen Medical

18
Degudent

18
Delta-q

18
Designer Ties

18
Diageo North Amer…

18
Direct Supply

18
Distance Oy

18
Dixie Consumer Pr…

18
Deuterx ◀

18

What this shows DeuteRx holds 18 patents at rank #15,959, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near DeuteRx

By rank, the assignees closest to #15,959 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in DeuteRx's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for DeuteRx, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), DeuteRx ranks #537 of 3,165 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (35 here).

GenMark Diagnostics, Inc. 35 Envision Aesc Energy Devices Ltd. 35 Optical Cable Corporation 35 W. Morrison Consulting Group Inc. 35

Deuterx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 Top 50% higher than 50% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

DeuteRx, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	2	11.1%
2016	2	11.1%
2017	4	22.2%
2018	2	11.1%
2019	3	16.7%
2020	1	5.6%
2021	1	5.6%
2022	2	11.1%
2024	1	5.6%

Which technologies does DeuteRx, LLC patent most?

C07D - Heterocyclic Compounds 16

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 14

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 12

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 11

Y02A - Technologies FOR Adaptation TO Climate Change 7

C07C - Acyclic OR Carbocyclic Compounds 2

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

DeuteRx, LLC's patent record in context - here's where to go next.

DeuteRx, LLC's lead technology class is C07D (Heterocyclic Compounds), 88.9% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #15,954 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare DeuteRx, LLC against DeGen Medical, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.